Lage MJ - Search Results

1

The impact of comorbid depression on adherence to therapy for multiple sclerosis.

Tarrants M, Oleen-Burkey M, Castelli-Haley J, Lage MJ. Tarrants M, et al. Among authors: lage mj. Mult Scler Int. 2011;2011:271321. doi: 10.1155/2011/271321. Epub 2011 Aug 2. Mult Scler Int. 2011. PMID: 22096632 Free PMC article.

2

Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.

Castelli-Haley J, Oleen-Burkey M, Lage MJ, Johnson KP. Castelli-Haley J, et al. Among authors: lage mj. Adv Ther. 2008 Jul;25(7):658-73. doi: 10.1007/s12325-008-0077-z. Adv Ther. 2008. PMID: 18641926

3

Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis.

Castelli-Haley J, Oleen-Burkey MA, Lage MJ, Johnson KP. Castelli-Haley J, et al. Among authors: lage mj. Adv Ther. 2009 May;26(5):552-62. doi: 10.1007/s12325-009-0028-3. Epub 2009 May 14. Adv Ther. 2009. PMID: 19444392

4

Glatiramer acetate and interferon beta-1a for intramuscular administration: a study of outcomes among multiple sclerosis intent-to-treat and persistent-use cohorts.

Castelli-Haley J, Oleen-Burkey MA, Lage MJ, Johnson K. Castelli-Haley J, et al. Among authors: lage mj. J Med Econ. 2010;13(3):464-71. doi: 10.3111/13696998.2010.496650. J Med Econ. 2010. PMID: 20662760 Free article.

5

Burden of a multiple sclerosis relapse: the patient's perspective.

Oleen-Burkey M, Castelli-Haley J, Lage MJ, Johnson KP. Oleen-Burkey M, et al. Among authors: lage mj. Patient. 2012;5(1):57-69. doi: 10.2165/11592160-000000000-00000. Patient. 2012. PMID: 22217263

6

The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate.

Oleen-Burkey MA, Dor A, Castelli-Haley J, Lage MJ. Oleen-Burkey MA, et al. Among authors: lage mj. J Med Econ. 2011;14(6):739-47. doi: 10.3111/13696998.2011.618517. Epub 2011 Sep 13. J Med Econ. 2011. PMID: 21913796 Free article.

7

Cost sharing, benefit design, and adherence: the case of multiple sclerosis.

Dor A, Lage MJ, Tarrants ML, Castelli-Haley J. Dor A, et al. Among authors: lage mj. Adv Health Econ Health Serv Res. 2010;22:175-93. doi: 10.1108/s0731-2199(2010)0000022011. Adv Health Econ Health Serv Res. 2010. PMID: 20575233

8

Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis.

Lage MJ, Castelli-Haley J, Oleen-Burkey MA. Lage MJ, et al. Work. 2006;27(2):143-51. Work. 2006. PMID: 16971761

9

Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations.

Velligan DI, Carroll C, Lage MJ, Fairman K. Velligan DI, et al. Among authors: lage mj. Psychiatr Serv. 2015 Feb 1;66(2):127-33. doi: 10.1176/appi.ps.201300085. Epub 2014 Oct 15. Psychiatr Serv. 2015. PMID: 25321616

10

Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment.

Lage MJ, Carroll CA, Fairman KA. Lage MJ, et al. J Med Econ. 2013 Sep;16(9):1146-53. doi: 10.3111/13696998.2013.823868. Epub 2013 Aug 8. J Med Econ. 2013. PMID: 23844620 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

86 results

Search Page

Filters